Last reviewed · How we verify
NCT06266585
Clinical Deterioration in Cerebral Venous Thrombosis: A Predictive Study
trial in Cerebral Venous Thrombosis in 273 participants. Completed in 1 January 2024.
31 December 2023
Quick facts
| Lead sponsor | Beijing Tiantan Hospital |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 273 |
| Start date | 1 January 2023 |
| Primary completion | 31 December 2023 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across China |
Conditions studied
- Cerebral Venous Thrombosis — all drugs for Cerebral Venous Thrombosis →
Sponsor
Beijing Tiantan Hospital
Who can join
18 and older, any sex, with Cerebral Venous Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this retrospective, prospective, multicenter cohort study is to determine the risk factors for deterioration of CVT patients after admission and establish a scoring model for risk stratification of patients. This study included two stages, the first stage was to enroll CVT patients from a single center from 2017 to 2022 for modeling, and the second stage was to enroll CVT patients from three centers in 2023 for external validation
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Development and validation of a score for clinical deterioration in patients with cerebral venous thrombosis.
Feng Y, Mo S, Li X, Jiang P, et al · · 2025 · cited 1× · PMID 39815140 · DOI 10.1007/s10143-025-03224-7
Verify or expand the search:
- PubMed search for NCT06266585
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cerebral Venous Thrombosis
Currently open trials in the same condition.
- NCT07352358 — Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis · Phase 4 · recruiting
- NCT06947707 — Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients · recruiting
- NCT06531122 — Rivaroxaban Versus Apixaban in Cerebral Venous Thrombosis · Phase 3 · recruiting
Other Beijing Tiantan Hospital trials
Trials by the same sponsor.
- NCT07341854 — Dexamethasone Palmitate for Postoperative Pain · NA · not yet recruiting
- NCT07527013 — Stratified Blood Pressure Management Strategy After Endovascular Treatment for Acute Ischemic Stroke · Phase 3 · not yet recruiting
- NCT07520370 — Effect of Perioperative Ulinastatin on Postoperative Stroke in Patients With Brain Tumor · NA · not yet recruiting
- NCT07526987 — Efficacy and Safety of Minocycline in Patients With Acute Ischaemic Stroke Receiving Intravenous Thrombolysis · Phase 3 · not yet recruiting
- NCT07591207 — The Efficacy and Safety of Loxoprofen Sodium Patch in Relieving Postoperative Pain After Laparoscopic Surgery · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06266585 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Tiantan Hospital
- Last refreshed: 20 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06266585.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing